Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + capecitabine + sorafenib for unresectable or metastatic renal cell carcinoma
2006-003429-95Phase 2Active
- Sponsor
- SOGUG
- Start
- Mar 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib, capecitabine and gemcitabine in renal cell carcinoma (RCC), sponsored by SOGUG. Primary endpoint: Progression-free survival. Started Mar 2012; status: active.
02
Drugs
sorafenibcapecitabinegemcitabine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-003429-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003429-95.